Osaka Medical College
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.osaka-med.ac.jp
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
Phase 2
Terminated
- Conditions
- Estrogen Receptor Negative NeoplasmBreast CancerHER-2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Osaka Medical College
- Target Recruit Count
- 30
- Registration Number
- NCT02598310
- Locations
- 🇯🇵
Osaka Medical College, Takatsuki, Osaka, Japan
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
Phase 2
Completed
- Conditions
- Breast CancerHER-2 Positive Breast CancerEffects of Chemotherapy
- Interventions
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2015-04-22
- Lead Sponsor
- Osaka Medical College
- Target Recruit Count
- 46
- Registration Number
- NCT01432223
- Locations
- 🇯🇵
Osaka Medical College, Takatsuki, Osaka, Japan
S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery
Phase 2
- Conditions
- Colorectal Cancer
- First Posted Date
- 2009-09-10
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Osaka Medical College
- Target Recruit Count
- 40
- Registration Number
- NCT00974389
- Locations
- 🇯🇵
Osaka Medical College, Takatsuki, Osaka, Japan
© Copyright 2025. All Rights Reserved by MedPath